Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues | Zendy

Jennifer R. Seal | Zendy; Michael R. Robinson | Zendy; James A. Burke | Zendy; Marina Bejanian | Zendy; Michael Coote | Zendy; Mayssa Attar | Zendy

Open Access

Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues

Author(s) -

Jennifer R. Seal,

Michael R. Robinson,

James A. Burke,

Marina Bejanian,

Michael Coote,

Mayssa Attar

Publication year - 2018

Publication title -

journal of ocular pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.727

H-Index - 61

eISSN - 1557-7732

pISSN - 1080-7683

DOI - 10.1089/jop.2018.0067

Subject(s) - bimatoprost , medicine , ophthalmology , intraocular pressure , glaucoma , pharmacology , ocular hypertension

To explore the ocular distribution of bimatoprost after intracameral administration of a biodegradable sustained-release bimatoprost implant (Bimatoprost SR) versus repeated topical administration of bimatoprost 0.03% ophthalmic solution in dogs. Bimatoprost SR and topical bimatoprost 0.03% previously were shown to have similar intraocular pressure-lowering effects in humans in a phase 1/2 clinical trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research